McKesson buys RxCrossroads
SAN FRANCISCO — McKesson Corp. has agreed to buy RxCrossroads, a provider of tailored services to pharmaceutical and biotechnology manufacturers, from CVS Health. The deal, expected to close early next year, is valued at $735 million, or about $635 million net of the present value of incremental cash tax benefits. It will be funded by